2024 SITC Annual Meeting
Updated Findings in Preventive Breast Cancer Vaccine Study
Researchers from Cleveland Clinic recently presented updated findings from a novel study of a vaccine aimed at preventing triple-negative breast cancer. The findings were presented at the Society for ...
Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma
Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-...
Study Highlights From MD Anderson Researchers
Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They ...
Study Finds In Situ Vaccination Using Tumor Treating Fields Plus Immune Checkpoint Inhibitors Extended Survival in Patients With Glioblastoma
A small study investigating tumor treating fields—an antimitotic electric fields therapy—in combination with pembrolizumab and temozolomide for the treatment of patients with glioblastoma was found to...
SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer
A phase II study by Riess et al investigating the IO102-IO103 vaccine plus pembrolizumab as first-line treatment in patients with non–small cell lung cancer (NSCLC) showed “promising” overall response...
